Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
- ribonucleic acid
- Technical Know How
- Medical Info
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 324840
Licensor grants a worldwide, nonexclusive right and license under any Licensor Technology and Licensor Patent Rights to screen Hits, Lead Compounds and Approved PLP Compounds in a Secondary Screening Program in order to identify inhibitors of any eubacterial, fungal and human Aminoacyl-tRNA Synthetases.
Program tRNA Synthetases mean the eubacterial Aminoacyl-tRNA Synthetases that charge the amino acids valine (VAL), glycine (GL Y), arginine (ARG), phenylalanine (PHE), histidine (HIS) and the fungal Aminoacyl-tRNA Synthetase that charges the amino acid tyrosine (TYR).
Covered Product means a product approved for marketing in a country for the diagnosis, treatment or prevention of human disease indications and (i) which has Inhibitory Activity against an Aminoacyl-tRNA Synthetase.
Area means research or development of compounds or agents having Inhibitory Activity useful in the treatment, prevention, or management of disease states in human beings.
IPSCIO Record ID: 324839
AMINOACYL-tRNA Synthetases means those enzymes responsible for the aminoacylation of tRNA molecules with their cognate amino acid.
Anti-infective agent means any compound resulting from the Collaboration with inhibitory activity/against a Program tRNA Synthetase or any other AMINOACYL-tRNA Synthetase.
Compound means any chemical entity or natural product sample that is identified as a HIT or synthesized in the Medicinal Chemistry and Drug Discovery Program; provided, however, that the term Compound shall not mean or include any Restricted Compound.
HIT means any compound in the Licensee Compound Library which, in the course of the Primary Screening Program, is shown to meet the criteria for inhibitory activity against a Program tRNA Synthetase, as such criteria is set forth in the Research Plan.
IPSCIO Record ID: 367570
For the Options, Licensor grants the exclusive right, exercisable at Licensees sole discretion, to elect to include any or all of the following as Licensee Development Compounds
– With respect to Project 1 the Candidate Selection Compound or PoC Compound, as applicable, from Project 1 that triggered Licensees right to exercise its Candidate Selection Option or PoC Option, as applicable, all Back-Up Compounds and Follow-On Compounds with respect thereto, and all other Collaboration Compounds under development in Project 1 that are Hits;
– With respect to each TPP Subprogram in Project 2, the PoC Compound from such Target Product Profile or TPP Subprogram in Project 2 that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included within such TPP Subprogram in Project 2 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC;
– With respect to Project 3, the PoC Compound that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included in Project 3 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC; and
– With respect to each TPP Subprogram in Project 4, the PoC Compound that triggered Licensees right to exercise its PoC Option, all Back-Up Compounds with respect thereto, and all other Collaboration Compounds included within such TPP Subprogram in Project 4 that have at a minimum achieved the Lead Declaration Criteria, as confirmed by the JRC.
For the Research Collaboration, Licensor grants a non-exclusive license under the Licensor IP, solely as and to the extent necessary or important to conduct activities for which Licensee is responsible under the Research Plans during the Research Collaboration Term.
For the Development and Commercialization, Licensor grants the exclusive right and license in the Territory, with the right to grant sublicenses, under the Licensor IP to make, have made, use, sell, offer for sale and import the Licensee Collaboration Compounds as and into Products in the Field during the Term.
Target means any of the following the hepatitis C virus protease; LeuRS; P-lactamase; or the Designated Target, which target shall be selected from the following two targets transpeptidase and signal peptidase.
Licensor Compound means a boron-containing small molecule compound Controlled by Licensor or a Licensor Affiliate.
LeuRS means bacterial leucyl tRNA synthetase.
PoC Compound means a Collaboration Compound resulting from PoC Trials.
The Field means any use or purpose, including the treatment, palliation, and/or prevention of any human or animal disease, disorder or condition; provided, however, that the Field shall specifically exclude the treatment, palliation, and/or prevention of onychomycosis.
Onychomycosis is a fungal infection of the nails that causes discoloration, thickening, and separation from the nail bed.
IPSCIO Record ID: 282907
— to conduct internal research and development, including without limitation drug discovery, screening and drug development, including without limitation
(A) to develop, make and use Nonexclusive Screens and to use Exclusive Screens in internal research and drug development, and to make and use Reporters and related reagents in connection therewith; and
(B) to practice any method, procedure or process covered thereby for internal research and drug development purposes; and
(C) to the extent covered thereby, to use the UHTSS and any related components sold to Licensee by Licensor for internal research and drug development purposes; and
(D) to use and modify the Software as permitted by this Agreement; and
— to the extent covered thereby to make, have made, use, sell, import and offer for sale any Hits, Lead Compounds, Approved PLP Compounds, Products, and substances identified as having Activity using such licensed rights, all in accordance with the terms and conditions of this Agreement.
The Software Licensor provides is a copy of the source code and object code for any Software provided with the UHTSS, or any Module or other component, to the extent available to and under the Control of Licensor, and, if such source or object code is licensed to Licensor from a third party, upon the same terms as apply to Licensors use of such source or object code.
Licensors Reporter System Technology means all Technology under the Control of Licensor or any of its Affiliates during the term of this Agreement which relates to the Reporter System or to the full exercise of the rights and benefits accorded Licensee hereunder pertaining to Licensees use of the Reporter System.
Licensor Technology means the Licensor Reporter System Technology and the Licensor UHTSS Technology.
Licensor UHTSS Patent Rights means all Patent Rights which are owned by or come under the Control of Licensor or its Affiliates during the term of this Agreement which relate to the UHTSS or to the full exercise of the rights and benefits accorded Licensee hereunder pertaining to Licensees use of the UHTSS.
Patents include Fluorogenic Substrates for Beta-Lactamase and Their Use in Assaying Reporter Gene Expression, Protein Localization, and Bacterial Resistance; Modified Green Fluorescent Proteins; Tandem Fluorescent Protein Constructs; Assays For Protein Kinases Using Fluorescent Protein Substrates; Voltage Sensing by Resonance Energy Transfer; Long Wavelength Mutant Fluorescent Proteins; Use of Promiscuous G-Proteins; Promiscuous G-Proteins Compositions and Their Use; and; Methods and Compositions for Sensitive and Rapid Functional Identification of Genomic Polynucleotides.
Ultra-high-throughput screening (uHTS) is an automated methodology for conducting hundreds of thousands of biological or chemical screening tests per day using liquid handling devices, sensitive detectors, robotics, data processing, and control software. The results of these experiments provide starting points for drug design and for understanding the interaction or role of a particular biochemical process in biology.
The automated storage and retrieval system for Licensee's UHTSS is designed to house more than 1,000,000 discrete compounds in solution for computer-controlled access. Aurora has developed an automated retrieval system for the module that can select and deliver specified compounds from this library of chemicals at a rate of at least 100,000 compounds per day for primary screening.
IPSCIO Record ID: 344537
This agreement includes a non-exclusive grant back to Licensor.
Compounds means compounds that were or are identified, synthesized, discovered, designed or acquired by or on behalf of (A) Licensor or its Affiliates either prior to the date hereof or during the Term, (B) Licensee or its Affiliates during the term of the Research and Development Program, or (C) a Non-ND Partner or its Affiliates either prior to the date hereof or during the Term, but only if during the term of a Non-ND Research Program; either are HDAC Inhibitors or (b) are developed pursuant to the Collaboration (subject to the last sentence of this defined term Compound); possess certain basic drug characteristics and range of chemotypes with pan and sub-type selective HDAC inhibition characteristics, as mutually agreed to by the Parties from time to time; and are used or useful in the Field.
HDAC means HDAC Class I and HDAC Class II, collectively.
HDAC Inhibitors means Small Molecules that directly inhibit HDAC Class I or HDAC Class II enzymatic activity or which have therapeutic effect through the inhibition of HDAC Class I or HDAC Class II enzymes.
Licensor Program Compounds means the approximately(Â± 5%) 1014 Compounds.
Field means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
'Applicable Field' means the Field, but only as to the disease indications within the Research and Development Program that is the subject of a Back-Out (i.e., the AD R&D Program, the HD R&D Program or the PD R&D Program), in each case including any of the Other Neurodegenerative Diseases.
IPSCIO Record ID: 203296
Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
Gene Expression Modulation by Small-molecules (GEMS) is PTCâ€™s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.
Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.